Smith Salley & Associates reduced its stake in shares of Illumina, Inc. (NASDAQ:ILMN) by 2.3% during the second quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission. The fund owned 2,214 shares of the life sciences company’s stock after selling 53 shares during the period. Smith Salley & Associates’ holdings in Illumina were worth $384,000 at the end of the most recent quarter.

A number of other hedge funds also recently bought and sold shares of the stock. Eastern Bank bought a new stake in Illumina during the first quarter valued at $256,000. Bank of Montreal Can increased its stake in Illumina by 61.0% in the first quarter. Bank of Montreal Can now owns 113,182 shares of the life sciences company’s stock valued at $19,314,000 after buying an additional 42,876 shares during the period. National Pension Service increased its stake in Illumina by 3.7% in the first quarter. National Pension Service now owns 122,352 shares of the life sciences company’s stock valued at $21,186,000 after buying an additional 4,331 shares during the period. Gulf International Bank UK Ltd increased its stake in Illumina by 1.4% in the first quarter. Gulf International Bank UK Ltd now owns 45,040 shares of the life sciences company’s stock valued at $7,685,000 after buying an additional 600 shares during the period. Finally, Forte Capital LLC ADV increased its stake in Illumina by 1.6% in the first quarter. Forte Capital LLC ADV now owns 2,185 shares of the life sciences company’s stock valued at $373,000 after buying an additional 35 shares during the period. Hedge funds and other institutional investors own 93.75% of the company’s stock.

Shares of Illumina, Inc. (NASDAQ:ILMN) opened at 174.33 on Friday. The stock has a market capitalization of $25.45 billion, a PE ratio of 35.28 and a beta of 0.84. Illumina, Inc. has a one year low of $119.37 and a one year high of $189.48. The stock has a 50 day moving average of $174.72 and a 200-day moving average of $171.38.

Illumina (NASDAQ:ILMN) last announced its quarterly earnings data on Tuesday, April 25th. The life sciences company reported $0.64 EPS for the quarter, meeting the Zacks’ consensus estimate of $0.64. Illumina had a net margin of 30.75% and a return on equity of 21.21%. The firm had revenue of $598 million for the quarter, compared to the consensus estimate of $590.51 million. During the same period in the previous year, the firm posted $0.71 earnings per share. The firm’s revenue was up 4.5% on a year-over-year basis. Equities analysts predict that Illumina, Inc. will post $3.63 earnings per share for the current fiscal year.

TRADEMARK VIOLATION WARNING: This piece was originally posted by Daily Political and is owned by of Daily Political. If you are accessing this piece on another domain, it was copied illegally and reposted in violation of United States & international copyright laws. The correct version of this piece can be read at https://www.dailypolitical.com/2017/07/28/smith-salley-associates-lowers-position-in-illumina-inc-nasdaqilmn.html.

Several research firms recently weighed in on ILMN. BidaskClub upgraded shares of Illumina from a “sell” rating to a “hold” rating in a report on Saturday, June 24th. Deutsche Bank AG reiterated a “hold” rating and issued a $175.00 target price (up previously from $165.00) on shares of Illumina in a report on Saturday, April 29th. Cowen and Company restated an “outperform” rating and issued a $200.00 price target on shares of Illumina in a research note on Wednesday, April 26th. Cantor Fitzgerald boosted their price target on shares of Illumina from $155.00 to $170.00 and gave the stock a “neutral” rating in a research note on Wednesday, April 26th. Finally, Vetr downgraded shares of Illumina from a “strong-buy” rating to a “buy” rating and set a $195.67 price target for the company. in a research note on Tuesday, April 25th. Four investment analysts have rated the stock with a sell rating, eight have given a hold rating, nine have issued a buy rating and one has assigned a strong buy rating to the company’s stock. The stock presently has an average rating of “Hold” and an average target price of $167.02.

In other Illumina news, SVP Charles Dadswell sold 1,609 shares of Illumina stock in a transaction that occurred on Wednesday, May 3rd. The shares were sold at an average price of $187.07, for a total value of $300,995.63. Following the completion of the sale, the senior vice president now directly owns 10,936 shares in the company, valued at $2,045,797.52. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is available through this hyperlink. Also, Director Jay T. Flatley sold 20,000 shares of Illumina stock in a transaction that occurred on Tuesday, May 9th. The shares were sold at an average price of $184.14, for a total transaction of $3,682,800.00. Following the completion of the sale, the director now owns 539,176 shares of the company’s stock, valued at $99,283,868.64. The disclosure for this sale can be found here. Insiders have sold 125,248 shares of company stock worth $22,281,673 over the last ninety days. 1.60% of the stock is currently owned by insiders.

About Illumina

Illumina, Inc (Illumina) is a provider of sequencing- and array-based solutions for genetic analysis. The Company operates through two segments: Core Illumina and the consolidated variable interest entities (VIEs), which include the activities of GRAIL, Inc (GRAIL) and Helix Holdings I, LLC (Helix). Core Illumina consists of its core operations.

Want to see what other hedge funds are holding ILMN? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Illumina, Inc. (NASDAQ:ILMN).

Institutional Ownership by Quarter for Illumina (NASDAQ:ILMN)

Receive News & Ratings for Illumina Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Illumina Inc. and related companies with MarketBeat.com's FREE daily email newsletter.